Which Ten Prescription Drugs Are the Most Profitable, and What Are Their Uses?
The top ten most profitable prescription medications worldwide are shown below, along with their respective applications:
Adalimumab, or Humira
Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, Crohn’s disease, and plaque psoriasis are among the indications.
Pembrolizumab (Keytruda)
Among other cancers, indications include lymphoma, lung cancer, and melanoma.
Lenalidomide, or Revlimid
Myelodysplastic syndromes, mantle cell lymphoma, and multiple myeloma are among the indications.
Apixaban, or Eliquis
Indications: To prevent stroke and blood clots in atrial fibrillation patients
Ibrutinib, or Imbruvica
B-cell cancers such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia are among the indications.
Aflibercept, or Eylea
Uses: To treat diabetic retinopathy, an eye condition linked to diabetes, age-related macular degeneration (AMD), and eye conditions linked to DME and AMD.
Ustekinumab, or Stelara
Treatment and management of Crohn’s disease, psoriatic arthritis, and plaque psoriasis are among the indications.
Nivolumab, or Opdivo
Among the solid tumors that immuno-oncology drugs can treat include melanoma, lung cancer, and renal cancer. Lung cancer, melanoma, and renal cell carcinoma are among the cancers that can be treated.
The Biktarvy
Indications: Treating HIV-1-infected adults and children with gland-borne illnesses.
(rivaroxaban) Xarelto
Indications include treating and managing deep vein thrombosis as well as preventing blood albumin clotting and stroke, especially in individuals with atrial fibrillation.
This list recognizes that the profitability of the pharmaceutical sector is not constant and can change due to a variety of circumstances, including changes in consumer preferences, the expiration of generics, and the release of ground-breaking medications.
It is advised that you directly confirm the information regarding these issues with a licensed medical professional or other suitable health care providers.
0 Comments